Aug 03 2016
Non-adherence to anti-retroviral therapy by HIV+ patients results in increased viral loads and risk of emergence of drug-resistant HIV strains. This poses a major public health threat. Lyndra Co. has developed an orally available, long-acting drug delivery system that it will now formulate to deliver anti-retrovirals. This will provide simplified oral therapeutic regimens that will increase adherence and accrue associated health benefits. In the long-term we will incorporate combinations of highly potent anti-HIV molecules into our dosage forms for use in HAART.